Patent classifications
A61P15/08
PROBIOTIC FOR THE TREATMENT OF INFERTILITY AND RECURRENT PREGNANCY LOSS
The invention relates to a strain of the Lactobacillus salivarius species deposited in the Spanish Type Culture Collection (CECT) with accession number 5713 or a mutant thereof for use in the treatment and/or prevention of infertility or recurrent pregnancy loss in a female subject. Additionally, the invention relates to an in vitro monitoring method for monitoring the effect of a treatment for infertility or recurrent pregnancy loss in a female subject with a strain of the Lactobacillus salivarius species deposited in the CECT with accession number 5713 or a mutant thereof.
PROBIOTIC FOR THE TREATMENT OF INFERTILITY AND RECURRENT PREGNANCY LOSS
The invention relates to a strain of the Lactobacillus salivarius species deposited in the Spanish Type Culture Collection (CECT) with accession number 5713 or a mutant thereof for use in the treatment and/or prevention of infertility or recurrent pregnancy loss in a female subject. Additionally, the invention relates to an in vitro monitoring method for monitoring the effect of a treatment for infertility or recurrent pregnancy loss in a female subject with a strain of the Lactobacillus salivarius species deposited in the CECT with accession number 5713 or a mutant thereof.
Heterocyclic compounds and uses thereof
Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
COMPOSITION COMPRISING HP-HMG FOR USE IN TREATING INFERTILITY
The present invention relates to improved assisted reproductive technology for women predicted to have a high ovarian response to controlled ovarian stimulation that comprise targeting a threshold serum hCG level by the final day of stimulation.
COMPOSITION COMPRISING HP-HMG FOR USE IN TREATING INFERTILITY
The present invention relates to improved assisted reproductive technology for women predicted to have a high ovarian response to controlled ovarian stimulation that comprise targeting a threshold serum hCG level by the final day of stimulation.
MONO- AND COMBINATION THERAPIES
Disclosed herein are compounds and combinations of compounds for treating a disease or condition, such as cancer.
MONO- AND COMBINATION THERAPIES
Disclosed herein are compounds and combinations of compounds for treating a disease or condition, such as cancer.
2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS
Provided are compounds represented by general formula (I), which can be used for treating ATR kinase-mediated diseases, such as proliferative diseases, such as cancer. Further provided are a pharmaceutical composition of the compound represented by general formula (I), a use thereof in treating ATR kinase-mediated diseases, and a preparation thereof.
##STR00001##
2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS
Provided are compounds represented by general formula (I), which can be used for treating ATR kinase-mediated diseases, such as proliferative diseases, such as cancer. Further provided are a pharmaceutical composition of the compound represented by general formula (I), a use thereof in treating ATR kinase-mediated diseases, and a preparation thereof.
##STR00001##
Salt inducible kinase inhibitors for enhancing fertility
This invention relates to methods of using salt inducible kinase inhibitors to enhance female fertility.